dolasetron has been researched along with Basal Ganglia Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carr, AA; Dudley, MW; Gittos, MW; Kehne, JH; Moser, P; Palfreyman, MG; Schmidt, CJ; Sorensen, SM | 1 |
| Bastit, P; Cals, L; Cappelaere, P; Catimel, G; Chevallier, B; Claverie, N; Fabbro, M; Giovannini, M; Khayat, D; Splinter, T; Wendling, JL | 1 |
1 trial(s) available for dolasetron and Basal Ganglia Diseases
| Article | Year |
|---|---|
A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy.
Topics: Acute Disease; Alcoholism; Antiemetics; Antineoplastic Agents; Basal Ganglia Diseases; Cisplatin; Double-Blind Method; Female; Headache; Humans; Indoles; Injections, Intravenous; Male; Metoclopramide; Middle Aged; Nausea; Neoplasms; Patient Satisfaction; Quinolizines; Remission Induction; Safety; Serotonin Antagonists; Sex Factors; Vomiting | 1997 |
1 other study(ies) available for dolasetron and Basal Ganglia Diseases
| Article | Year |
|---|---|
Electrophysiological, biochemical and behavioral evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic function.
Topics: Animals; Basal Ganglia Diseases; Behavior, Animal; Dopamine; Electrophysiology; Fluorobenzenes; Indoles; Male; Mice; Microdialysis; Motor Activity; N-Methyl-3,4-methylenedioxyamphetamine; Neurons; Piperidines; Quinolizines; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Serotonin Antagonists | 1993 |